Next, to examine whether necrostatin-1 treatment ameliorated osteopenia in EtOH-treated mice, we treated the mice with 1.65 mg/kg/d of Nec-1 for 22 weeks and BMMSCs with 50 μM of Nec-1 for 48 h, respectively (Supplementary Figure S3c, d). This evidence concerns the gene PCSK1 and Osteopenia.